Analyst Price Targets — IMNM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 10:07 am | Supawat Thongthip | Truist Financial | $37.00 | $22.11 | StreetInsider | Immunome Inc. (IMNM) PT Raised to $37 at Truist Securities, Assumes Coverage |
| May 28, 2026 7:36 am | Lukas Shumway | Barclays | $36.00 | $22.11 | StreetInsider | Barclays Starts Immunome Inc. (IMNM) at Overweight |
| May 15, 2026 10:25 am | Andrew Berens | Leerink Partners | $33.00 | $22.02 | TheFly | Immunome price target lowered to $33 from $37 at Leerink |
| February 12, 2026 11:05 am | — | H.C. Wainwright | $40.00 | $23.41 | TheFly | Immunome initiated with a Buy at H.C. Wainwright |
| December 16, 2025 1:41 pm | — | Lake Street | $32.00 | $23.39 | TheFly | Immunome price target raised to $32 from $22 at Lake Street |
| December 16, 2025 1:06 pm | — | Evercore ISI | $40.00 | $23.35 | TheFly | Immunome price target raised to $40 from $18 at Evercore ISI |
| December 15, 2025 8:05 pm | — | Leerink Partners | $40.00 | $22.65 | TheFly | Immunome price target raised to $40 from $38 at Leerink |
| December 1, 2025 12:08 pm | Karina Rabayeva | Truist Financial | $36.00 | $18.42 | TheFly | Immunome initiated with a Buy at Truist |
| November 17, 2025 12:08 pm | — | Stephens | $33.00 | $17.14 | StreetInsider | Immunome Inc. (IMNM) PT Raised to $33 at StephensMember Login |
| September 5, 2025 11:46 am | — | Craig-Hallum | $26.00 | $10.52 | TheFly | Immunome initiated with a Buy at Craig-Hallum |
Latest News for IMNM
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the company.
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid…
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of…
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMNM.
U.S. House Trading
No House trades found for IMNM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.